AnaptysBio, Inc.
ANAB · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $91 | $17 | $10 | $63 |
| % Growth | 432% | 66.8% | -83.7% | – |
| Cost of Goods Sold | $164 | $132 | $89 | $98 |
| Gross Profit | -$73 | -$115 | -$79 | -$35 |
| % Margin | -79.5% | -671% | -763.2% | -55.9% |
| R&D Expenses | $164 | $140 | $89 | $98 |
| G&A Expenses | $42 | $42 | $37 | $21 |
| SG&A Expenses | $42 | $42 | $37 | $21 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$164 | -$132 | -$89 | -$98 |
| Operating Expenses | $42 | $49 | $37 | $21 |
| Operating Income | -$115 | -$164 | -$115 | -$57 |
| % Margin | -125.9% | -958.3% | -1,119.4% | -89.9% |
| Other Income/Exp. Net | -$30 | $1 | -$14 | -$1 |
| Pre-Tax Income | -$145 | -$164 | -$129 | -$58 |
| Tax Expense | $0 | -$0 | $0 | $0 |
| Net Income | -$145 | -$164 | -$129 | -$58 |
| % Margin | -159.1% | -953.7% | -1,251.3% | -91.5% |
| EPS | -5.12 | -6.08 | -4.57 | -2.11 |
| % Growth | 15.8% | -33% | -116.6% | – |
| EPS Diluted | -5.12 | -6.08 | -4.57 | -2.11 |
| Weighted Avg Shares Out | 28 | 27 | 28 | 27 |
| Weighted Avg Shares Out Dil | 28 | 27 | 28 | 27 |
| Supplemental Information | – | – | – | – |
| Interest Income | $20 | $19 | $8 | $0 |
| Interest Expense | $50 | $18 | $21 | $1 |
| Depreciation & Amortization | $2 | $1 | $2 | $2 |
| EBITDA | -$93 | -$156 | -$105 | -$56 |
| % Margin | -101.6% | -911.7% | -1,023.2% | -88.2% |